DexCom price target raised to $109 from $107 at BTIG

BTIG raised the firm’s price target on DexCom (DXCM) to $109 from $107 and keeps a Buy rating on the shares after its Q1 results. Revenue topped expectations and a big beat in U.S. sales shows the company is back on track, while its operating expense control offsets gross margin pressures, the analyst tells investors in a research note.